David Cibula
Impact in
- Obstetrics and Gynecology top 0.01%
- Endometrial and Cervical Cancer Treatments
- Reproductive Medicine top 0.05%
- Ovarian cancer diagnosis and treatment
- Ovarian function and disorders
Papers in
-
- Endometrial and Cervical Cancer Treatments 219
- Uterine Myomas and Treatments 9
-
- Ovarian cancer diagnosis and treatment 114
- Ovarian function and disorders 21
- Co-authors
- Michal Zikan (76 shared papers)D. Fischerová (81 shared papers)Ladislav Dušek (38 shared papers)Pavel Dundr (70 shared papers)Nadeem R. Abu‐Rustum (17 shared papers)Jiri Sláma (52 shared papers)Martin Hill (30 shared papers)Jana Vrbíková (17 shared papers)
- Journals
- International Journal of Gynecological Cancer (126 papers)Gynecologic Oncology (60 papers)Annals of Oncology (20 papers)Ultrasound in Obstetrics and Gynecology (19 papers)Journal of Clinical Oncology (14 papers)
- Partner nations
- CzechiaItalyUnited States
In The Last Decade
David Cibula
440 papers receiving 18.3k citations
David Cibula's Hit Papers
Peers
Comparison fields: 5 of 140
- Obstetrics and Gynecology 7.8k
- Reproductive Medicine 5.1k
- Oncology 2.4k
- Radiology, Nuclear Medicine and Imaging 891
- Cancer Research 504
Countries citing papers authored by David Cibula
This map shows the geographic impact of David Cibula's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Cibula with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Cibula more than expected).
Fields of papers citing papers by David Cibula
This network shows the impact of papers produced by David Cibula. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Cibula. The network helps show where David Cibula may publish in the future.
Co-authors
The 25 scholars most cited alongside David Cibula, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 481 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma Hit paper breakdown → | 2020 | 1388 |
| 2 | ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up Hit paper breakdown → | 2015 | 1081 |
| 3 | ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease Hit paper breakdown → | 2019 | 900 |
| 4 | Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer Hit paper breakdown → | 2023 | 560 |
| 5 | 2014 | 477 | |
| 6 | A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms Hit paper breakdown → | 2019 | 407 |
| 7 | The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer Hit paper breakdown → | 2018 | 393 |
| 8 | Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study Hit paper breakdown → | 2021 | 329 |
| 9 | ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* Hit paper breakdown → | 2023 | 297 |
| 10 | Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer Hit paper breakdown → | 2023 | 287 |
| 11 | The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer Hit paper breakdown → | 2018 | 284 |
| 12 | 2000 | 227 | |
| 13 | 2020 | 225 | |
| 14 | 2011 | 223 | |
| 15 | 2020 | 209 | |
| 16 | 2010 | 203 | |
| 17 | 2017 | 201 | |
| 18 | 2018 | 201 | |
| 19 | 2020 | 193 | |
| 20 | 2010 | 180 |
About David Cibula
David Cibula is a scholar working on Obstetrics and Gynecology, Reproductive Medicine, Oncology, Epidemiology and Public Health, Environmental and Occupational Health, having authored 481 papers that have together received 18.8k indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (219 papers), Ovarian cancer diagnosis and treatment (114 papers), PARP inhibition in cancer therapy (31 papers), Cervical Cancer and HPV Research (23 papers), Ovarian function and disorders (21 papers), Epigenetics and DNA Methylation (17 papers), Reproductive Health and Contraception (9 papers) and Uterine Myomas and Treatments (9 papers). The work is most often cited by research in Obstetrics and Gynecology (7.8k citations), Reproductive Medicine (5.1k citations), Oncology (2.4k citations), Radiology, Nuclear Medicine and Imaging (891 citations) and Cancer Research (504 citations). David Cibula has collaborated with scholars based in Czechia, Italy and United States. Frequent co-authors include Michal Zikan, D. Fischerová, Ladislav Dušek, Pavel Dundr, Nadeem R. Abu‐Rustum, Jiri Sláma, Martin Hill, Jana Vrbíková, Denis Querleu and Martin Widschwendter. Their work appears in journals such as International Journal of Gynecological Cancer, Gynecologic Oncology, Annals of Oncology, Ultrasound in Obstetrics and Gynecology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.